Endometrial Cancer | Topics

 
Pembrolizumab Demonstrates Sustained, Robust Clinical Activity in Advanced MSI-H/dMMR Endometrial Cancer
January 11, 2022

Patients with microsatellite instability–high and mismatch repair–deficient advanced endometrial cancer experienced a long lasting benefit following treatment with pembrolizumab.

Vaginal Cuff Brachytherapy for Endometrial Cancer Yields Low Toxicity
January 06, 2022

Patients with endometrial cancer who were treated with 30 Gy of 6 fractions of vaginal cuff brachytherapy presented with lower toxicity.

High Tumor Mutational Burden Associated with High Responses to Dostarlimab Monotherapy for Endometrial Cancer
September 16, 2021

Investigators identified a link between high tumor mutational burden and high responses to dostarlimab among patients with endometrial cancer.

FDA Grants Full Approval For Lenvatinib and Pembrolizumab Combination in Advanced dMMR/MSI-H Endometrial Cancer
July 22, 2021

Phase 3 results demonstrating the superiority of the pembrolizumab plus lenvatinib combination vs standard chemotherapy served as a confirmatory trial for its approval in certain patients with advanced endometrial cancer.

PD-1 Inhibitor Dostarlimab Earns Accelerated Approval in Mismatch Repair Deficient Endometrial Cancer
April 22, 2021

Based on results from the phase 2 GARNET trial, dostarlimab may be used to treat recurrent or advanced endometrial cancer progressing on or after treatment with a platinum-containing chemotherapy that is mismatch repair deficient.

Phase 2 ENPAC Trial Shows Feasibility of Enzalutamide Triplet in Endometrioid Endometrial Cancer
March 25, 2021

The androgen receptor inhibitor enzalutamide, an approved therapy for certain types of prostate cancer, has shown activity for the treatment of patients with recurrent or advanced endometrioid endometrial cancer.

Addition of Olaparib to Cediranib Does Not Induce Superior Efficacy in Advanced Endometrial Cancer
March 22, 2021

The combination of cediranib and olaparib demonstrated modest efficacy in patients with recurrent, metastatic, or persistent endometrial cancer; however, this was not significantly different compared to cediranib alone.

Pembrolizumab/Lenvatinib Combo Shows Survival Benefit in Advanced Endometrial Cancer
March 19, 2021

Following a prior announcement that the phase 3 KEYNOTE-775 trial met both primary end points of progression-free and overall survival benefit, data for the pembrolizumab/lenvatinib combination were presented at the Society of Gynecologic Oncology 2021 Annual Meeting on Women’s Cancer.

Study Suggests NACT to be Important Treatment Option for Metastatic Endometrial Cancer
December 27, 2020

“These findings suggest that similar to its benefits in ovarian cancer, NACT could potentially lower perioperative morbidity and may serve as an important treatment option among women with metastatic endometrial cancer,” the study authors wrote.

Phase 3 KEYNOTE-775/Study 309 Trial Meets Dual Primary End Points in Advanced Endometrial Cancer
December 16, 2020

The pivotal phase 3 KEYNOTE-775/Study 309 trial evaluating the investigational use of pembrolizumab (Keytruda) plus lenvatinib (Lenvima) met its dual primary end points of overall and progression-free survival in patients with advanced endometrial cancer.